Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.55 |
| ▸ | KDM4A | O75164 | 4/20 | 0.55 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | INSR | P06213 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7619893 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10341093 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10340951 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10340879 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6653604 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16183109 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10340880 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3054036 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10341094 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16183107 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970325-B1 | LYSOPHOSPHATIDIC ACID DETECTION | UNIV PORTLAND STATE (US) | 2017-09-27 | — | — | EP | claimed |
| US-20100222673-A1 | INTRA-OPERATIVE HEAD AND NECK NERVE MAPPING | NOVADAQ TECHNOLOGIES INC. (CA) | 2010-09-02 | — | — | US | claimed |
| WO-2007016790-A1 | INTRA-OPERATIVE HEAD & NECK NERVE MAPPING | NOVADAQ TECHNOLOGIES, INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| EP-1039834-B1 | OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE | IMARX PHARMACEUTICAL CORP (US) | 2005-09-28 | — | — | EP | claimed |
| EP-4702841-A1 | MICROCAPSULES FOR CONTROLLED RELEASE IN ENCLOSED MEDIA | Centre Scientifique Et Technique Du Batiment (CSTB) (FR) | 2026-03-04 | — | — | EP | disclosed |
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4121774-A1 | MEANS AND METHOD FOR DETECTING ABERRANT ERYTHROBLASTS | Premise Biosystems Co., Ltd. (TH) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021186032-A1 | MEANS AND METHOD FOR DETECTING ABERRANT ERYTHROBLASTS | PREMISE BIOSYSTEMS CO., LTD. (TH) | 2021-09-23 | — | — | WO | disclosed |
| US-10231624-B2 | Intra-operative head and neck nerve mapping | NOV ADAQ TECHNOLOGIES ULC (CA) | 2019-03-19 | — | — | US | disclosed |
| US-20180153984-A1 | ADJUVANT PARTICLES COMPRISING ADENOSINE RECEPTOR ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-07 | — | — | US | disclosed |
| US-8357675-B2 | 17-alpha-substituted derivatives of estradiol with wound-healing activity | EUTICALS S.P.A. (IT) | 2013-01-22 | — | — | US | disclosed |
| EP-1910398-B1 | 17-ALPHA-SUBSTITUTED DERIVATIVES OF ESTRADIOL WITH WOUND-HEALING ACTIVITY | PRIME EUROP THERAPEUTICALS (IT) | 2010-11-24 | — | — | EP | disclosed |
| US-20100222673-A1 | INTRA-OPERATIVE HEAD AND NECK NERVE MAPPING | NOVADAQ TECHNOLOGIES INC. (CA) | 2010-09-02 | — | — | US | disclosed |
| US-20100035796-A1 | 17-ALPHA-SUBSTITUTED DERIVATIVES OF ESTRADIOL WITH WOUND-HEALING ACTIVITY | EUTICALS S.P.A. (IT) | 2010-02-11 | — | — | US | disclosed |
| WO-2007016790-A1 | INTRA-OPERATIVE HEAD & NECK NERVE MAPPING | NOVADAQ TECHNOLOGIES, INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
| EP-0348497-A1 | NON-LINEAR OPTICAL MATERIAL CONTAINING A HEMICYANINE COMPOUND AND PROCESS FOR PRODUCING IT | MERCK PATENT GmbH (DE) | 1990-01-03 | — | — | EP | disclosed |
| WO-1989005843-A1 | NON-LINEAR OPTICAL MATERIAL CONTAINING A HEMICYANINE COMPOUND AND PROCESS FOR PRODUCING IT | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | MAP1LC3B, MAP1LC3A, SQSTM1 | CHRM2 3349/4885CHRM4 3130/4885CHRM5 4169/4885 |
| US-20100035796-A1 | 17-ALPHA-SUBSTITUTED DERIVATIVES OF ESTRADIOL WITH WOUND-HEALING ACTIVITY | HSD17B11, CYP19A1, ESR1 | CHRM2 848/4885CHRM4 1406/4885CHRM5 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.